Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y, Weygant N, Qu D, May R, Berry WL, Yao J, Chandrakesan P, Zheng W, Zhao L, Zhao KL, Drake M, Vega KJ, Bronze MS, Tomasek JJ, An G, Houchen CW. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.
-
Alternative Splicing
-
Alternative Splicing
-
Animals
-
Animals
-
Antineoplastic Agents
-
Antineoplastic Agents
-
Apoptosis
-
Apoptosis
-
Biomarkers, Tumor
-
Biomarkers, Tumor
-
Carcinoma, Renal Cell
-
Carcinoma, Renal Cell
-
Cell Movement
-
Cell Movement
-
Cell Proliferation
-
Cell Proliferation
-
Cell Transformation, Neoplastic
-
Cell Transformation, Neoplastic
-
Drug Resistance, Neoplasm
-
Drug Resistance, Neoplasm
-
Epithelial-Mesenchymal Transition
-
Epithelial-Mesenchymal Transition
-
Follow-Up Studies
-
Follow-Up Studies
-
Humans
-
Humans
-
Intracellular Signaling Peptides and Proteins
-
Intracellular Signaling Peptides and Proteins
-
Kidney Neoplasms
-
Kidney Neoplasms
-
Male
-
Male
-
Mice
-
Mice
-
Mice, Nude
-
Mice, Nude
-
Neoplastic Stem Cells
-
Neoplastic Stem Cells
-
Prognosis
-
Prognosis
-
RNA, Small Interfering
-
RNA, Small Interfering
-
Survival Rate
-
Survival Rate
-
Tumor Cells, Cultured
-
Tumor Cells, Cultured
-
Xenograft Model Antitumor Assays
-
Xenograft Model Antitumor Assays